Add to a list

Inactive Instrument

Oxeco PLC Share Price London S.E.

OXE

GB00B1J5QT30

Advanced Medical Equipment & Technology

OTC Markets Traded

End-of-day quote London S.E.
- ^GBX	-

07-11	Tissue Regenix Group plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-19	Tissue Regenix Group Ltd Appoints Timothy James Sturm as Director, Effective January 13, 2026	CI

Last Transcript : Oxeco PLC

Tissue Regenix Group plc, H1 2025 Earnings Call, Sep 30, 2025

03/10/25

More transcripts

Managers and Directors : Oxeco PLC

Manager	Title	Age	Since
Jay LeCoque CEO	Chief Executive Officer	64	15/10/2025
Kirsten Lund DFI	Director of Finance/CFO	-	16/10/2025
Judy Madden COO	Chief Operating Officer	-	04/01/2026

Director	Title	Age	Since
Kirsten Lund BRD	Director/Board Member	-	16/10/2025
Jay LeCoque CHM	Chairman	64	07/09/2025
Judy Madden BRD	Director/Board Member	-	04/01/2026

More insiders

Medical Software & Technology Services

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VEEVA SYSTEMS INC.	+15.20%	+12.40%	-1.54%	+49.17%	39.78B
PRO MEDICUS LIMITED	-2.90%	-9.86%	-40.72%	+144.63%	13.82B
SECTRA AB	+3.21%	-1.19%	-17.82%	+65.52%	5.55B
HEARTFLOW, INC.	-1.72%	+5.64%	+53.28%	-	4.26B
GENERATE BIOMEDICINES, INC.	-2.29%	-7.07%	-	-	2.07B
OMNICELL, INC.	-0.12%	-8.29%	+2.11%	-42.29%	1.53B
XUNFEI HEALTHCARE TECHNOLOGY CO., LTD.	-2.10%	-2.04%	-38.07%	-	1.1B
ARBUTUS BIOPHARMA CORPORATION	-0.39%	+3.82%	+41.64%	+154.68%	1.03B
SUZHOU MEDICALSYSTEM TECHNOLOGY CO., LTD.	+3.08%	-0.89%	+52.67%	+70.79%	1.01B
Average	+1.32%	-1.09%	+6.44%	+73.75%	7.79B
Weighted average by Cap.	+8.13%	-2.85%	-6.45%	+71.51%

See all sector performances

Tissue Regenix Group Ltd, formerly Tissue Regenix Group plc, regenerative medicine company specializing in medical devices and allografts. The Company is focused on the development of regenerative products utilizing its two platform technologies, dCELL, addressing soft tissue decellularization process, removing DNA and Cellular material to reduce risk of rejection; and BioRinse technology, is a natural bone filler solution. Its proprietary dCELL and BioRinse technologies underpin a focused portfolio of xenograft and allograft products. Its products categories include Musculoskeletal, DermaPure, Soft Tissue-OrthoPure XT, and Birth Tissue. The Musculoskeletal product includes ConCelltrate 100, Conventional GGrafts, MatrixCellect 100 DBM, Matrix OI Cortical Fibers & Fillers, and others. The DermaPure product is a next generation decellularized dermal allograft. The DermaPure product is available in three configurations: DermaPure, DermaPure Non-Oriented, and DermaPure Meshed.

Employees

Sector

Advanced Medical Equipment & Technology

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	6.9M 5.93M 5.55M 5.08M 9.57M 659M 9.6M 65.7M 25.68M 332M 25.92M 25.36M 1.1B	P/E 2024	-74.8x	P/E 2025	-0.6x
Enterprise Value	18.63M 16M 14.98M 13.71M 25.83M 1.78B 25.9M 177M 69.32M 897M 69.96M 68.45M 2.97B	EV / Sales 2024	2.17x	EV / Sales 2025	0.66x
Free-Float	78.79%	Yield 2024 *	-	Yield 2025	-

07-11	Tissue Regenix Group plc Reports Earnings Results for the Full Year Ended December 31, 2025	CI
01-19	Tissue Regenix Group Ltd Appoints Timothy James Sturm as Director, Effective January 13, 2026	CI
01-19	Tissue Regenix Group plc Appoints Geoffrey Joseph Fitzhugh Gorman as Director, Effective January 13, 2026	CI
01-13	Tissue Regenix Group plc Announces Termination of George Brian Phillips as Director, Effective January 9, 2026	CI
01-13	Tissue Regenix Group Ltd Announces Termination of Directorship of Professor Shervanthi Homer Vanniasinkam Effective January 8, 2026	CI
01-07	Galantas Gold buys Andacollo Oro gold project	AN
01-07	Tissue Regenix Group Delists from London Bourse's AIM Segment	MT
01-06	CellRight Technologies, LLC announced that it has received funding from Tissue Regenix Group plc, Harwood Capital LLP	CI
12-08	Tissue Regenix's London Trading Halt to Continue Until Delisting in January 2026	MT
12-08	Tissue Regenix does not believe it will be able to clarify co's financial position ahead of proposed cancellation date	RE
12-03	Tissue Regenix Group plc announced that it expects to receive £17.5 million in funding	CI
12-01	Tissue Regenix Gets Emergency Overdraft to Stay Solvent; Funding Needs Remain	MT
12-01	Tissue Regenix secures $500k emergency overdraft	RE

17/04/24	Tissue Regenix : Final results presentation for the year ended 31 December 2023	PU
21/03/24	Tissue Regenix unveils growth strategy and positive EBITDA milestone	AQ
05/09/23	Tissue Regenix Group says "disciplined approach" paying off at half-year stage	AQ
27/03/23	Tissue Regenix Group looking to expand sales beyond the US	AQ
21/03/23	Tissue Regenix : Annual Report and Financials for year ended 31 December 2022	PU

	2024	2025
Net sales	28.65M 24.59M 23.02M 21.08M 39.71M 2.74B 39.82M 273M 107M 1.38B 108M 105M 4.56B	28.43M 24.4M 22.85M 20.92M 39.41M 2.72B 39.52M 271M 106M 1.37B 107M 104M 4.53B
Net income	-713K -612K -573K -525K -988K -68.1M -991K -6.79M -2.65M -34.32M -2.68M -2.62M -114M	-11.14M -9.56M -8.95M -8.2M -15.44M -1.06B -15.49M -106M -41.44M -536M -41.83M -40.92M -1.77B
Net Debt	8.6M 7.38M 6.91M 6.32M 11.91M 821M 11.95M 81.79M 31.97M 414M 32.27M 31.57M 1.37B	11.73M 10.07M 9.43M 8.63M 16.26M 1.12B 16.31M 112M 43.64M 565M 44.04M 43.09M 1.87B

Oxeco PLC Share Price London S.E.

Stocks

OXE

GB00B1J5QT30

Advanced Medical Equipment & Technology

Valuation : Oxeco PLC

Latest news : Oxeco PLC

Last Transcript : Oxeco PLC

Press Releases : Oxeco PLC

Managers and Directors : Oxeco PLC

Medical Software & Technology Services

Financials

Company Profile